MedeliX
Start asking

ramucirumab

Cyramza · ATC code L01FX06

Also known as: Ramusirumab

Key facts
Active substance
ramucirumab
ATC code
L01FX06
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Cyramza 10 mg/ml concentrate for solution for infusion
Marketing authorisation holder
Eli Lilly Nederland B.V.
Information as of
2026-10-29

Key facts

Ramucirumab (Cyramza) is a monoclonal antibody against VEGF receptor 2, given as an antiangiogenic infusion for several advanced cancers.

What it is used for

  • Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after platinum and fluoropyrimidine chemotherapy: with paclitaxel or as monotherapy.
  • Metastatic colorectal cancer after bevacizumab, oxaliplatin and a fluoropyrimidine: with FOLFIRI.
  • Non-small cell lung cancer: with erlotinib first line for activating EGFR mutations; with docetaxel after platinum-based chemotherapy.
  • Advanced or unresectable hepatocellular carcinoma with AFP ≥ 400 ng/ml after sorafenib: monotherapy.

Dosing

  • Gastric cancer with paclitaxel: 8 mg/kg on days 1 and 15 of a 28 day cycle before paclitaxel; as a single agent 8 mg/kg every 2 weeks.
  • Colorectal cancer: 8 mg/kg every 2 weeks before FOLFIRI.
  • NSCLC: with erlotinib 10 mg/kg every two weeks; with docetaxel 10 mg/kg on day 1 of a 21 day cycle.
  • Hepatocellular carcinoma: 8 mg/kg every 2 weeks.
  • Premedication with an H1 antagonist before each infusion; dose reductions for proteinuria, interruption for severe hypertension and for at least 4 weeks before elective surgery (see the full text).

Contraindications

  • Hypersensitivity to the active substance or any excipient.
  • In NSCLC: tumour cavitation or tumour involvement of major vessels.

Important warnings

  • Serious, sometimes fatal arterial thromboembolic events (e.g. myocardial infarction, stroke); permanently discontinue after a severe event.
  • Gastrointestinal perforations and severe bleeding; permanently discontinue after perforation.
  • Infusion-related reactions, mostly with the first infusions; discontinue immediately and permanently for Grade 3 or 4.
  • Severe hypertension: monitor blood pressure before each dose; aneurysms and artery dissections may occur.
  • Impaired wound healing and proteinuria up to nephrotic syndrome.

Side effects

  • Monotherapy, most common: peripheral oedema, hypertension, diarrhoea, abdominal pain, headache, proteinuria and thrombocytopenia.
  • With chemotherapy, most common: fatigue/asthenia, neutropenia, diarrhoea, epistaxis and stomatitis.
  • Most serious: gastrointestinal perforation, severe gastrointestinal haemorrhage, arterial thromboembolic events and posterior reversible encephalopathy syndrome.

Interactions

  • No interactions were observed with paclitaxel, irinotecan, docetaxel or erlotinib.

Pregnancy and breastfeeding

  • Not recommended during pregnancy or in women not using contraception; contraception until 3 months after the last dose.
  • Breast-feeding should be discontinued during treatment and for at least 3 months after the last dose.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • CyramzaEli Lilly Nederland B.V. · EMEA/H/C/002829

Source: European Medicines Agency (EMA), product information

Turkey

  • CyramzaLİLLY İLAÇ TİC. LTD. ŞTİ. · 3 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Cyramza
Liechtenstein
Cyramza
Norway
Cyramza

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Cyramza – EPAR, Product Information. 2026-10-29. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.